DURHAM – Life sciences firm Bioventus is gearing up to launch its IPO this week, looking to raise as much as $125 million.
The stock was priced at between $16 and $18 last week but has yet to being trading as of Monday morning,
“Bioventus is offering 7,350,000 shares of its Class A common stock. The initial public offering price is expected to be between $16.00 and $18.00 per share,” the company said of its latest IPO effort.
“Bioventus expects to grant the underwriters a 30-day option to purchase up to an additional 1,102,500 shares of its common stock at the initial public offering price to cover over-allotments.”
For the firm’s formal filing, check this site: https://www.sec.gov/Archives/edgar/data/1665988/000119312521028021/d58473ds1a.htm?source=content_type%3Areact%7Cfirst_level_url%3Aarticle%7Csection%3Amain_content%7Cbutton%3Abody_link
The company expects to list shares on the Nasdaq Global Select Market under the ticker symbol “BVS.”
Check this site for the latest news: https://www.nasdaq.com/market-activity/stocks/bvs
Major Wall Street firms Morgan Stanley, J.P. Morgan Securities and Goldman Sachs as well as Canaccord Genuity are handling the offering.
